General Information
Drug ID
DR00313
Drug Name
Cefadroxil
Synonyms
(6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid; BL-S 578; BL-S578; CDX; Cefadroxil (JP15); Cefadroxil anhydrous; Cefadroxilo; Cefadroxilo [INN-Spanish]; Cefadroxilum; Cefadroxilum [INN-Latin]; Cephadroxil; Curisafe (TN); D-Cefadroxil; MJF-11567-3; S 578; S-578; Sumacef; Sumacef (TN)
Drug Type
Small molecular drug
Indication Gram-positive & negative bacteria infections [ICD11: 1A00-1H0Z] Approved [1]
Therapeutic Class
Antibiotics
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=47965"></iframe>
3D MOL 2D MOL
Formula
C16H17N3O5S
Canonical SMILES
CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O
InChI
InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1
InChIKey
BOEGTKLJZSQCCD-UEKVPHQBSA-N
CAS Number
CAS 66592-87-8
Pharmaceutical Properties Molecular Weight 363.388 Topological Polar Surface Area 158
Heavy Atom Count 25 Rotatable Bond Count 4
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 7
XLogP
-2.1
PubChem CID
47965
PubChem SID
103620148 , 103914339 , 104133801 , 104354273 , 10990583 , 11335584 , 11360823 , 11362958 , 11365520 , 11368082 , 11373871 , 11376244 , 11461795 , 11466462 , 11467582 , 11483750 , 11486123 , 11487903 , 11492081 , 11493918 , 121363085 , 124766005 , 14852631 , 16050996 , 24892921 , 25622160 , 34712894 , 46509128 , 47440185 , 47515253 , 47515254 , 47959665 , 48035040 , 48334422 , 48415709 , 49699087 , 50124273 , 57654040 , 75439952 , 7847323 , 7978892 , 8149235 , 85279381 , 87322627 , 90451718 , 9095 , 92125414 , 93576133 , 93576712 , 99301497
ChEBI ID
CHEBI:3479
TTD Drug ID
D0X9ZC
DT(s) Transporting This Drug MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [2]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [2]
MRP3 Transporter Info Multidrug resistance-associated protein 3 Substrate [2]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [2]
PEPT1 Transporter Info Peptide transporter 1 Substrate [3]
PEPT2 Transporter Info Peptide transporter 2 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data MRP1 Transporter Info Km = 3.9 microM Human embryonic kidney cells (HEK293)-MRP1 [2]
MRP3 Transporter Info Km = 2.5 microM Spodoptera frugiperda 21 (Sf21) cells-MRP3 [2]
MRP4 Transporter Info Km = 0.25 microM Spodoptera frugiperda 21 (Sf21) cells-MRP4 [2]
PEPT1 Transporter Info Km = 7.97 microM Human cervical cancer cell line (Hela)-PEPT1 [3]
PEPT2 Transporter Info Km = 150.8 microM In vivo model (human) [4]
References
1 Cefadroxil was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
3 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
4 Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.